Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus plus corticosteroids for polymyositis/dermatomyositis-associated interstitial pneumonitis (IMPPACT)
jRCT1091220012Completed
- Sponsor
- IMPPACT Study Central Office
- Start
- Jul 2007
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of tacrolimus in polymyositis (PM), dermatomyositis (DM), amyopathic dermatomyositis (ADM) and 1 more (2 arms), sponsored by IMPPACT Study Central Office. Primary endpoint: Overall survival. Started Jul 2007; status: completed.
02
Drugs
tacrolimus
03
Conditions
polymyositis (PM)dermatomyositis (DM)amyopathic dermatomyositis (ADM)interstitial pneumonia
Beyond the preview
Go deeper on jRCT1091220012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220012.